VEGFR2 peptide vaccine (VAXIMM)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameVEGFR2 peptide vaccine (VAXIMM)
Drug Alias NameVEGFR2 specific T cell vaccineVXM-01
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Development/production technology > Live attenuated vaccine
Mechanisms of ActionImmunostimulantsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsPancreatic NeoplasmsColorectal NeoplasmsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesBCM Europe AGChina Medical System Holdings LtdVaximm Gmbh +[4] 
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsPancreatic NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A